Date Of Encounter Research Articles

Otolaryngology Diagnoses at a Student-Run Community Clinic.

Purpose Compared to insured individuals who have established pathways for primary and specialist care, uninsured patients often delay seeking medical attention and are more likely to rely on emergency departments or community clinics for low-cost services. This study aims to identify the most prevalent otolaryngology (ENT) diagnoses at a free, student-run community clinic for uninsured patients. Additionally, it seeks to elucidate their management needs in order to inform strategies for enhancing support and care for this vulnerable population. Methods The electronic medical records for a free, student-run community clinic (St. Vincent's Hope Student Clinic in Galveston, Texas) were reviewed. Patient age, sex, chief complaint, date of medical encounter, and encounter diagnoses from April 2021 to May 2024 were recorded; medical diagnoses were then manually stratified into system categories and diagnostic subgroups. Diagnoses unrelated to ENT were excluded and likely represented secondary encounter diagnoses. Results A total of 38 patients were evaluated across 51 total ENT encounters. The average number of encounters per patient per year was 1.34 (1.05-1.63, 95% CI). The most common ENT category was throat (37%), and the most common individual diagnosis was balance problems (11% of total diagnoses). Conclusion The most common ENT system was the throat, followed by ear, nose, and other. Balance problems, reflux, and allergic rhinitis were the most common individual ENT diagnoses. The analysis of data collected for this study may help direct future care and resource allocation at this clinic.

Daymet and DeGAUSS: Development of a Novel Method that Links High Spatial Resolution Gridded Meteorological Data with Geocoded Healthcare Encounters

ObjectiveDue to human-caused climate change, extreme temperature-related morbidity/mortality are increasing global public health concerns. To better understand the burdens of heat exposure, researchers must merge accurate/granular environmental data with clinical data. We developed a privacy-preserving method that links high-spatial-resolution continuous, gridded, meteorological data to geocoded healthcare encounters. ApproachIn an R environment, we developed code that links geocoded healthcare encounters to publicly-available Daymet data via the corresponding Daymet raster cell number and healthcare encounter date. Daymet provides daily 1km x 1km surface meteorological data over North America since 1980. User specifications include the bounding box latitude/longitude of Daymet data download, which Daymet environmental variables are linked, and the day-lag of Daymet data matching to healthcare encounter date. ResultsLinking 500,000 healthcare encounters over a 7-day lag with 7 years of Daymet data comprising minimum/maximum temperature over a bounding box encompassing Cook County, Illinois (5,670 1km raster cells) took 11.92 minutes with 4 CPUs and 8GB RAM. Thirteen years of Daymet data took 23.85 minutes. Linking 7.5 million encounters with 7 years of data took 28.49 minutes. ConclusionsOur newly-developed method for linking Daymet data to geocoded healthcare encounters preserves patient privacy, and processes the data efficiently over a minimal timespan. ImplicationsDaymet data linked to healthcare encounters allows for accurate assessment of the association between environmental variable exposure and any clinical outcome over North America. Packaging the code allows for public distribution within the Decentralized Geomarker Assessment for Multi-Site Studies (DeGAUSS) universe of geoanalytic tools.

All-cause claims analysis of the LATERA absorbable nasal implant vs surgical repair in patients with nasal valve collapse

Aims To compare all-cause claims associated with the LATERA Absorbable Nasal Implant and surgical repair of nasal vestibular stenosis in patients with nasal valve collapse. Methods This retrospective cohort study utilized data from STATinMED RWD Insights. A defined set of HCPCS, ICD-10-CM and CPT codes were used to identify patients with ≥1 claim for a LATERA procedure, and patients with ≥1 claim for surgical repair between June 1, 2015– March 31, 2023. Patients with continuous capture for at least 12 months before and at least 6 months after the index date were selected. The index date was defined as earliest date of encounter for a LATERA or surgical repair procedure. Inverse probability of treatment weighting (IPTW) was used to ensure balance between cohorts. Descriptive analyses were provided for all claims data using standard summary statistics. All-cause claims were assessed during the baseline, index date, and follow-up period. Chi-squared tests and independent sample t-tests were used to assess differences in cohorts for categorical and continuous variables, respectively. Results The study population included 5,032 LATERA patients and 26,553 surgical repair patients. During the baseline and follow-up periods, the matched cohorts exhibited similar all-cause claims. On the index date, LATERA patients incurred lower claims vs. surgical repair, likely due to LATERA’s ability to be implanted in the physician office setting. LATERA patients and surgical repair patients mean (SD) total costs were $9,612 [$14,930] vs $11,846 [$17,037] (p ≤ 0.0001), respectively. Conclusions Treatment with the LATERA Absorbable Nasal Implant is a potentially cost saving option for payers on the index date compared to traditional surgical repair in patients with nasal valve collapse due to the ability to be performed in the office. All-cause claims were similar in the baseline and follow-up periods. When performed with concomitant procedures, all-cause claims during follow-up were similar between groups.

The risk and risk factors of chikungunya virus infection and rheumatological sequelae in a cohort of U.S. Military Health System beneficiaries: Implications for the vaccine era.

Understanding the risk of chikungunya virus (CHIKV) infection and rheumatic sequelae across populations, including travelers and the military, is critical. We leveraged healthcare delivery data of over 9 million U.S. Military Health System (MHS) beneficiaries to identify cases, and sampled controls, to estimate the risk of post-CHIKV rheumatic sequelae. MHS beneficiary CHIKV infections diagnosed 2014-2018 were identified from the Disease Reporting System internet, TRICARE Encounter Data Non-Institutional, and Comprehensive Ambulatory/Professional Encounter Record systems. Non-CHIKV controls were matched (1:4) by age, gender, beneficiary status, and encounter date. The frequency of comorbidities and incident rheumatic diagnoses through December 2018 were derived from International Classification of Diseases codes and compared between cases and controls. Poisson regression models estimated the association of CHIKV infection with rheumatic sequelae. We further performed a nested case-control study to estimate risk factors for post-CHIKV sequelae in those with prior CHIKV. 195 CHIKV cases were diagnosed between July 2014 and December 2018. The median age was 42 years, and 43.6% were active duty. 63/195 (32.3%) of CHIKV cases had an incident rheumatic diagnosis, including arthralgia, polyarthritis, polymyalgia rheumatica, and/or rheumatoid arthritis, compared to 156/780 (20.0%) of controls (p < 0.001). CHIKV infection remained associated with rheumatic sequelae (aRR = 1.579, p = 0.008) after adjusting for prior rheumatic disease and demography. Those with rheumatic CHIKV sequelae had a median 7 healthcare encounters (IQR 3-15). Among CHIKV infections, we found no association between post-CHIKV rheumatic sequelae and demography, service characteristics, or comorbidities. CHIKV infection is uncommon but associated with rheumatic sequelae among MHS beneficiaries, with substantial healthcare requirements in a proportion of cases with such sequelae. No demographic, clinical, or occupational variables were associated with post-CHIKV rheumatic sequelae, suggesting that prediction of these complications is challenging in MHS beneficiaries. These findings are important context for future CHIKV vaccine decision making in this and other populations.

Case validation of bloodstream infections with an antibiotic-resistant organism

Background: Bloodstream infections (BSIs) are an important cause of morbidity and mortality in severely ill patients, contributing to increased length of hospital stay and higher cost of care. Alberta Health Services Infection Prevention and Control (IPC) conducts inpatient surveillance of new episodes of BSIs with methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) or carbapenemase-producing organisms (CPO) in 112 acute care facilities. A case-finding process was undertaken to verify the accuracy of BSI data entry. Methods: All positive MRSA, VRE or CPO blood cultures in 2021 were linked to the Inpatient Discharge Abstract Database (DAD) and the National Ambulatory Care Reporting System (NACRS) to identify new cases during acute care admissions. The results were then compared to surveillance records captured by infection control professionals (ICPs). Cases with unmatched culture date and/or encounter date and cases not identified by ICPs were screened by the study team with final decision made by ICPs. Results were analyzed by ARO and by % increase in number of surveillance records. Results: The laboratory linkage identified 286 new cases. Comparing to surveillance records (n = 248) captured by ICPs, 137 (57.3%) had matching collection dates and encounter dates, 85 (35.6%) had close matches on collection dates and encounter dates, 17 (7.1%) records had either matching collection dates or encounter dates, and 1 (0.4%) record did not have any matches on dates. There were 46 records identified in the laboratory data that were not in the surveillance system and 8 records that were in the surveillance system but not matched to the laboratory data. After review, 22 Surveillance records had data entry errors (1 CPO BSI, 20 MRSA BSI, and 1 VRE BSI), and there were 14 BSI records found to be missing (13 MRSA BSI, 1 VRE BSI). This represents a 6% increase in MRSA BSI and a 3% increase in VRE BSI identified in 2021 and no increase in CPO BSI. Conclusions: A laboratory validation to determine if BSIs with an ARO were missed during routine IPC surveillance identified a small proportion of missed bloodstream infections. The most common reason for the miss was admission through the emergency department with multiple blood cultures collected during a single admission. These results will be shared with the Infection Control program to facilitate correct BSI capture.

Artificial intelligence approaches for phenotyping heart failure in U.S. Veterans Health Administration electronic health record.

Heart failure (HF) is a clinical syndrome with no definitive diagnostic tests. HF registries are often based on manual reviews of medical records of hospitalized HF patients identified using International Classification of Diseases (ICD) codes. However, most HF patients are not hospitalized, and manual review of big electronic health record (EHR) data is not practical. The US Department of Veterans Affairs (VA) has the largest integrated healthcare system in the nation, and an estimated 1.5 million patients have ICD codes for HF (HF ICD-code universe) in their VA EHR. The objective of our study was to develop artificial intelligence (AI) models to phenotype HF in these patients. The model development cohort (n=20000: training, 16000; validation 2000; testing, 2000) included 10000 patients with HF and 10000 without HF who were matched by age, sex, race, inpatient/outpatient status, hospital, and encounter date (within 60days). HF status was ascertained by manual chart reviews in VA's External Peer Review Program for HF (EPRP-HF) and non-HF status was ascertained by the absence of ICD codes for HF in VA EHR. Two clinicians annotated 1000 random snippets with HF-related keywords and labelled 436 as HF, which was then used to train and test a natural language processing (NLP) model to classify HF (positive predictive value or PPV, 0.81; sensitivity, 0.77). A machine learning (ML) model using linear support vector machine architecture was trained and tested to classify HF using EPRP-HF as cases (PPV, 0.86; sensitivity, 0.86). From the 'HF ICD-code universe', we randomly selected 200 patients (gold standard cohort) and two clinicians manually adjudicated HF (gold standard HF) in 145 of those patients by chart reviews. We calculated NLP, ML, and NLP+ML scores and used weighted F scores to derive their optimal threshold values for HF classification, which resulted in PPVs of 0.83, 0.77, and 0.85 and sensitivities of 0.86, 0.88, and 0.83, respectively. HF patients classified by the NLP+ML model were characteristically and prognostically similar to those with gold standard HF. All three models performed better than ICD code approaches: one principal hospital discharge diagnosis code for HF (PPV, 0.97; sensitivity, 0.21) or two primary outpatient encounter diagnosis codes for HF (PPV, 0.88; sensitivity, 0.54). These findings suggest that NLP and ML models are efficient AI tools to phenotype HF in big EHR data to create contemporary HF registries for clinical studies of effectiveness, quality improvement, and hypothesis generation.

Risk of dementia in older veterans with multiple sclerosis

BackgroundWhile it is widely accepted that multiple sclerosis (MS) often causes cognitive dysfunction, it is thought that these cognitive symptoms rarely progress to dementia. However, this has not been thoroughly investigated. The objectives of this cohort study are to determine whether people with MS have an increased risk of dementia compared to the general population and to identify factors, such as geographic latitude, which may modify this association. MethodsWe studied data from a random sample of US veterans aged ≥ 55 years followed at Veterans Affairs Health Care Systems nationwide from 1999 to 2019. We identified all patients diagnosed with MS using ICD codes over a two-year baseline period. We then identified a comparison cohort of patients without MS matched 1:1 on sex, age, race, and first encounter date. We constructed Cox proportional hazards regression models to determine the association between MS and dementia while controlling for demographic factors and comorbidities, with additional models to examine subgroup effects. We used Fine-Gray subdistribution hazard models accounting for competing risk of death to evaluate the sensitivity of the findings. ResultsThe study included 4084 MS patients and a matched group of 4084 non-MS patients. Overall, patients had mean age 66, were 93.6% male, and 88.1% non-Hispanic White, with mean follow-up time 9.5 years (MS) and 10.8 years (non-MS). In unadjusted models, veterans with MS had greater risk of dementia compared to matched controls (cumulative incidence 16.7% vs 12.4%; Cox HR 1.58, 95% CI 1.41–1.78). The increased risk remained after adjustment for potential confounders (adjusted HR 1.56, 95% CI 1.39–1.76) and when considering death as a competing risk (Fine-Gray HR 1.36, 95% CI 1.21–1.53). The magnitude of the MS-dementia association increased with rising geographic latitude (North HR 1.86, 1.51–2.30; Central HR 1.61, 1.42–1.82; South HR 1.39, 1.18–1.64; interaction p = 0.04) and younger baseline age (interaction p<0.001). ConclusionsAmong older veterans with MS, risk of dementia diagnosis was higher compared to matched controls even after controlling for comorbidities. The risk difference was highest in northern regions and in younger patients. Clinicians caring for older MS patients should be aware of this risk and offer screening and treatment accordingly.

Health care utilization and outcomes of patients seen by virtual urgent care versus in-person emergency department care.

Virtual urgent care (VUC) is intended to support diversion of patients with low-acuity complaints and reduce the need for in-person emergency department visits. We aimed to describe subsequent health care utilization and outcomes of patients who used VUC compared with similar patients who had an in-person emergency department visit. We used patient-level encounter data that were prospectively collected for patients using VUC services provided by 14 pilot programs in Ontario, Canada. We linked the data to provincial administrative databases to identify subsequent 30-day health care utilization and outcomes. We defined 2 subgroups of VUC users; those with a documented prompt referral to an emergency department by a VUC provider, and those without. We matched patients in each cohort to an equal number of patients presenting to an emergency department in person, based on encounter date, medical concern and the logit of a propensity score. For the subgroup of patients not promptly referred to an emergency department, we matched patients to those who were seen in an emergency department and then discharged home. Of the 19 595 patient VUC visits linked to administrative data, we matched 2129 patients promptly referred to the emergency department by a VUC provider to patients presenting to the emergency department in person. Index visit hospital admissions (9.4% v. 8.7%), 30-day emergency department visits (17.0% v. 17.5%), and hospital admissions (12.9% v. 11.0%) were similar between the groups. We matched 14 179 patients who were seen by a VUC provider with no documented referral to the emergency department. Patients seen by VUC were more likely to have a subsequent in-person emergency department visit within 72 hours (13.7% v. 7.0%), 7 days (16.5% v. 10.3%) and 30 days (21.9% v. 17.9%), but hospital admissions were similar within 72 hours (1.1% v. 1.3%), and higher within 30 days for patients who were discharged home from the emergency department (2.6% v. 3.4%). The impact of the provincial VUC pilot program on subsequent health care utilization was limited. There is a need to better understand the inherent limitations of virtual care and ensure future virtual providers have timely access to in-person outpatient resources, to prevent subsequent emergency department visits.

Incidence of Cardiovascular Disease and Venous Thromboembolism in Patients With Atopic Dermatitis.

Atopic dermatitis (AD) may increase risk for atherothrombotic and cardiovascular (CV) disease. Determine CV disease and venous thromboembolism risk among patients with AD. Cohort study using electronic health data from U.K. general practices in 1994 to 2015. Children (<18 y) and adults (≥18 y) with AD were matched to patients without AD on age, same practice, and encounter date. Treatments and specialist referrals served as proxies of AD severity. Outcomes were incident myocardial infarction, cerebrovascular accident (CVA), diabetes, hypertension, dyslipidemia, deep vein thrombosis (DVT), and pulmonary embolism. Cox regression analysis was used to compare outcomes in AD versus non-AD patients. Comparing 409,341 children with AD (93.2% mild, 5.5% moderate, and 1.3% severe) to 1,809,029 unaffected children, AD was associated with higher risk of DVT (hazard ratio [HR] 1.23; 95% confidence interval [95% CI] 1.02-1.48) and severe AD was associated with higher risk of CVA (HR 2.43; 95% CI 1.13-5.22) and diabetes (HR 1.46; 95% CI 1.06-2.01). Comparing 625,083 adults with AD (65.7% mild, 31.4% moderate, and 2.9% severe) to 2,678,888 unaffected adults, AD, especially when severe, was associated with higher risk of DVT (HR 1.14; 95% CI 1.11-1.18; and HR 1.64; 95% CI 1.49-1.82, respectively) and small but increased risks of CVA, diabetes, and dyslipidemia. Adults with severe AD had higher risk of myocardial infarction (HR 1.27; 95% CI 1.15-1.39), CVA (HR 1.21; 95% CI 1.13-1.30), diabetes (HR 1.15; 95% CI 1.09-1.22), dyslipidemia (HR 1.11; 95% CI 1.06-1.17), and pulmonary embolism (HR 1.39; 95% CI 1.21-1.60) compared with adults without AD. Atopic dermatitis, particularly when severe, is associated with small but increased risks of CV risk factors and events and significantly increased risk of venous thromboembolism.

Population Analysis of SABR/SRS for the Treatment of Metastatic Cancer in a Jurisdiction of 15 Million People

Stereotactic Ablative Radiotherapy (SABR) or Stereotactic Radiosurgery (SRS) for oligometastatic cancer or oligoprogression of metastatic cancer is supported by an expanding body of evidence in the literature. The degree of uptake of these techniques, supplanting traditional and potentially less resource-intensive techniques in this patient population, would be of interest to clinicians and administrators alike. A review of provincial date for Ontario, Canada (population ∼ 15 million) was performed to quantify the use of SABR/SRS to metastases either in the brain or elsewhere in the body. Data was obtained from a new (April 2022) activity-based hospital funding model, responsible for ALL radiation treatment remuneration at all facilities across the province (i.e., single payer system). Funding is triggered when a patient is treated as per 1 or more of the ∼270 provincial radiation protocols, defined as a "protocol instance". Protocols were developed by clinicians across Ontario according to a consensus-based iterative process, considering provincial, national and international guidelines and/or evidence-based practice. Prerequisite information for remuneration included (but was not limited to): patient demographics, identification of whether a primary tumor or metastasis(es) was treated, protocol, radiation technique, dose/fractionation, and encounter dates. Submission of data was performed by the 17 hospitals who provide radiation services and logic checked centrally by the provincial cancer agency following submission. Validation of data is performed by ongoing iterative processes. From April 1 to November 30, 2022, a total of 31,916 radiation protocol instances were funded for 27,298 patients. Of these, 4,156 (13%) were SABR/SRS protocols. When only treatment to metastases were considered, the total number of SABR/SRS protocol instances was 3,024 (9.5% of total) and 29.4% of the total number of protocol instances delivered to metastases (10,271). The 29.4% was split further as 1567 protocol instances (15.3%) to brain metastases and 1457 protocol instances elsewhere in the body, most often to lung (3.9%), spine (3.4%), non-spine bone (2.2%) and liver (1.7%), with a further 2.9% to unspecified extra-cranial metastases. Data for all 17 Ontario treatment facilities revealed a range of SABR/SRS usage for metastases from 1.8 to 59.8% (median 23.2%, IQ range 16.9%). On review of recently submitted data, nearly 1/3 of all radiation treatments to metastases in Ontario are delivered using a SABR/SRS technique. There is wide regional variation in the use of these techniques. Reasons for this variation require further investigation.

Abstract PO-081: Patterns of immune susceptibility in young, non-smoking, oral cancer patients

Abstract Introduction: Oral squamous cell carcinoma (OSCC) is peculiarly increasing in non-smokers, many of whom are younger than traditional, smoking related OSCC. The cause of this trend is unknown, and it is unclear whether these cancers represent a distinct disease, as compared to smoking-related OSCC. We hypothesize that young non-smokers with OSCC have immunological differences that increase susceptibility to infectious and immunological disease (including cancer) as compared to smokers with OSCC. Therefore, we investigated the incidence of bacterial, viral, and autoimmune illness in young OSCC patients. Methods: We performed a retrospective cohort study at a single tertiary care institution of patients under age 55 diagnosed with OSCC from 2003-2021. Multiple encounters for the same ICD-10 code in the same year were counted as one. Bacterial infections included bacterial pneumonia (ICD-10 J13-J15), cellulitis and lymphangitis (L03), urinary tract infection (N39.0), and post-surgical infection (T81.4). Viral infections included viral pneumonia (J10-J12), skin herpesvirus (A60, A63, B00, B07), infectious mononucleosis (B27), herpes zoster-related infections (B02), HIV (B20), viral hepatitis (B15-19), CMV disease (B25), viral conjunctivitis (B30), and other unclassified viral diseases (B33-34). Autoimmune disease included rheumatoid arthritis (M05), systemic Lupus (M32, L93), psoriasis (L40), inflammatory bowel disease (K50-52), Sjogren disease (M35.0), type 1 diabetes (E10), multiple sclerosis (G35), myasthenia gravis (G70), and autoimmune thyroiditis (E06.3). When patients were known to be deceased, but date of death was unavailable, they were presumed deceased at date of last encounter. Kaplan Meier analysis was used to analyze survival. Poisson regression was used to model the incidence of illness. Results: In total, 749 patients were analyzed; 467 were never smokers (NS) and 282 were current or former smokers (S). In NS, median age (interquartile range) was 47.9 (40.4-51.9) and 267 (57.2%) were male. In S, median age was 49.3 (44.6-52.7) and 208 (73.8%) were male. Five-year OS was 89% (95% confidence interval 86-93%) in NS vs. 89% (85%-93%) in S (p=0.66). The incidence of bacterial infection was 25.9 per 1000 person-years (py) in NS vs. 37.0/1000py in S (p&amp;lt;0.01). The incidence of viral infection was 37.8/1000py in NS vs. 31.4/1000py in S (p=0.14). The incidence of autoimmune disease was 26.7/1000py in NS and 36.0/1000py in S (p=0.02). Conclusions: NS were more likely to be female vs. S. OS was similar between NS and S. The incidence of bacterial infections and autoimmune diseases were significantly higher in S vs. NS, in line with pre-existing evidence that smoking is associated with increased susceptibility to bacterial infection and increased incidence and severity of autoimmune disease. Interestingly, there was a trend towards increased viral infections in NS vs. S, although not statistically significant. In the context of pre-existing evidence showing that smoking increases risk of viral infection, this finding warrants further study. Citation Format: Maxwell Y. Lee, Fred M. Baik, John B. Sunwoo. Patterns of immune susceptibility in young, non-smoking, oral cancer patients [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-081.

Disparities in Pediatric Orthopedic Surgery Care During the COVID-19 Pandemic Pre-vaccine and Post-Vaccine Availability.

The COVID-19 pandemic has led to significant disruptions in medical care, resulting in an estimated 40% of US adults avoiding care. However, the return to baseline health care utilization following COVID-19 restrictions within the pediatric orthopedic population remains unexplored. We sought to analyze the visit volume and demographics of pediatric orthopedic patients at 3 timepoints: prepandemic (2019), pandemic (2020), and pandemic post-vaccine availability (2021), to determine the impact of COVID-19 restrictions on our single-center, multisite institution. We performed a retrospective cohort study of 6318 patients seeking treatment at our institution from May through August in 2019, 2020, and 2021. Patient age, sex, address, encounter date, and ICD-10 codes were obtained. Diagnoses were classified into fractures and dislocations, non-fracture-related trauma, sports, elective, and other categories. Geospatial analysis comparing incidence and geospatial distribution of diagnoses across the time periods was performed and compared with the Centers for Disease Control (CDC) social vulnerability index (SVI). The total number of pediatric orthopedic visits decreased by 22.2% during the pandemic ( P <0.001) and remained 11.6% lower post-vaccine availability compared with prepandemic numbers ( P <0.001). There was no significant difference in age ( P =0.097) or sex ( P =0.248) of the patients across all 3 timepoints; however, patients seen during the pandemic were more often White race (67.7% vs. 59.3%, P <0.001). Post-vaccine availability, trauma visits increased by 18.2% ( P <0.001) and total fractures remained 13.4% lower than prepandemic volume ( P <0.001). Sports volume decreased during the pandemic but returned to prepandemic volume in the post-vaccine availability period ( P =0.298). Elective visits did not recover to prepandemic volume and remained 13.0% lower compared with baseline ( P <0.001). Geospatial analysis of patient distribution illustrated neighborhood trends in access to care during the COVID-19 pandemic, with fewer patients from high SVI and low socioeconomic status neighborhoods seeking fracture care during the pandemic than prepandemic. Post-vaccine availability, fracture population distribution resembled prepandemic levels, suggesting a return to baseline health care utilization. Pediatric orthopedic surgery visit volume broadly decreased during the COVID-19 pandemic and did not return to prepandemic levels. All categories increased in the post-vaccine availability time point except elective visits. Geospatial analysis revealed that neighborhoods with a high social vulnerability index (SVI) were associated with decreased fracture visits during the pandemic, whereas low SVI neighborhoods did not experience as much of a decline. Future research is needed to study these neighborhood trends and more completely characterize factors preventing equitable access to care in the pediatric orthopedic population. Retrospective Study, Level III.

Burden of Crohn’s Disease in the United States Medicaid Population, 2010–2019

Twenty-five percent of the United States population is enrolled in Medicaid. Rates of Crohn's disease (CD) have not been estimated in the Medicaid population since the Affordable Care Act expansion in 2014. We aimed to estimate the incidence and prevalence of CD by age, sex, and race. We identified all 2010-2019 Medicaid CD encounters using codes from the International Classification of Diseases, Clinical Modification versions 9 and 10. Individuals with ≥2 CD encounters were included. Sensitivity analyses were performed on other definitions (eg, ≥1 CD encounter). Incidence required ≥1 year of Medicaid eligibility prior to first CD encounter date (2013-2019). We calculated CD prevalence and incidence using the entire Medicaid population as the denominator. Rates were stratified by calendar year, age, sex, and race. Poisson regression models examined CD-associated demographic characteristics. We compared demographics and treatments of the entire Medicaid population with the multiple CD case definitions using percent and median. A total of 197,553 beneficiaries had ≥2 CD encounters. The CD point prevalence per 100,000 persons rose from 56 (2010) to 88 (2011) to 165 (2019). CD incidence per 100,000 person-years was 18 (2013) and 13 (2019). Higher incidence and prevalence rates correlated with female, white, or multiracial beneficiaries. Prevalence rates rose in later years. Incidence decreased over time. From 2010 to 2019, Medicaid population CD prevalence increased while incidence decreased from 2013 to 2019. Overall Medicaid CD incidence and prevalence ranges align with prior large administrative database studies.

Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults

BackgroundIgG4-related disease (IgG4-RD) is an immune-mediated condition that can affect nearly any organ or anatomic site. We sought to describe the epidemiology of IgG4-RD in the USA.MethodsWe used Optum’s deidentified...

Renal Mass Biopsy Mandate Is Associated With Change in Treatment Decisions.

To prevent avoidable treatment and make more informed care decisions about small renal masses, the use of renal mass biopsies has increased since the early 2000s. In April 2017, Atrium Health Carolinas Medical Center began requiring biopsies before all percutaneous thermal ablation procedures for renal masses. We aim to determine the effect of this preablation biopsy mandate on small renal mass treatment decisions. Our study is a retrospective analysis of a prospectively managed database designed to track patients with small renal masses presented at the Kidney Tumor Program from 2000-2020. We separated patients into 2 cohorts (pre- and postmandate) based on the initial encounter date, excluding those from April 2017-April 2018 to allow for implementation of the mandate. We also excluded patients with masses >4 cm. Overall, we found no significant difference between the pre- and postmandate cohorts, with race as an exception. Implementation of the mandate coincided with an increase in biopsies for both ablation and nonablation treatment pathways (P < .001, P = .01). Renal mass biopsy rates increased in all socioeconomic groups except the lowest quartile. Additionally, Black/Hispanic patients had the highest biopsy rate. We found significant changes in treatment decisions between our cohorts: surgery decreased 24% (P < .001), active surveillance increased 28% (P < .001), and patients with no follow-up decreased 8% (P = .03). Our data indicate that a preablation renal mass biopsy mandate is associated with the wider use of biopsies for all small renal mass patients, fewer surgical interventions, and an increase in active surveillance.

Can clinical characteristics differentiate patients with unexplained chronic cough from patients with asthma and COPD?

Background: Chronic cough is reported in up to 20% of the adult population and often persists despite medical treatment with currently available therapies. Many clinical conditions, including asthma and chronic obstructive pulmonary disease (COPD), must be excluded before making a Unexplained chronic cough diagnosis. Methods: The primary objective was to use a large hospital dataset to compare clinical features of patients with a primary diagnosis of UCC with those with asthma or COPD without a primary diagnosis of UCC to help clinicians differentiate between these conditions more readily. Data were collected for all hospitalization and outpatient medical encounters for each patient between November 2013 and December 2018. Information included demographics, encounter dates, medications prescribed at every encounter for chronic cough, lung function testing, and hematologic parameters. Asthma and COPD were combined into one group to ensure there was no overlap with UCC and due to limitations of International Classification of Diseases coding to confirm an asthma(A)/COPD diagnosis. Results: Female gender represented 70% of encounters for UCC versus 61.8% for asthma/COPD (p < 0.0001); the mean age was 56.9 years for UCC versus 50.1 years for A/COPD (p < 0.0001). The number of patients on cough medications and the cough medication frequency were significantly higher in the UCC versus A/COPD group (p < 0.0001). UCC versus A/COPD patients had a total of eight versus three cough-related encounters over the study duration (i.e., 5 years) (<0.0001). The average interval between successive encounters was less for UCC (114 days) versus the A/COPD (288 days) group. Gender-adjusted Forced expiratory volume in the first second of exhalation/Forced vital capacity (FEV1/FVC) ratios, residual volume%, and Diffusion capacity for carbon monoxide (DLCO%) were significantly higher in UCC versus A/COPD, whereas the response to bronchodilators of FEV1, FVC and residual volumes were significantly greater in A/COPD patients. Conclusions: Clinical characteristics differentiating UCC from A/COPD could accelerate recognition of UCC diagnosis especially in the subspecialty setting where patients with these disorders are referred.

Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network.

Following historically low influenza activity during the 2020-2021 season, the United States saw an increase in influenza circulating during the 2021-2022 season. Most viruses belonged to the influenza A(H3N2) 3C.2a1b 2a.2 subclade. We conducted a test-negative case-control analysis among adults ≥18 years of age at 3 sites within the VISION Network. Encounters included emergency department/urgent care (ED/UC) visits or hospitalizations with ≥1 acute respiratory illness (ARI) discharge diagnosis codes and molecular testing for influenza. Vaccine effectiveness (VE) was calculated by comparing the odds of influenza vaccination ≥14 days before the encounter date between influenza-positive cases (type A) and influenza-negative and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative controls, applying inverse probability-to-be-vaccinated weights, and adjusting for confounders. In total, 86 732 ED/UC ARI-associated encounters (7696 [9%] cases) and 16 805 hospitalized ARI-associated encounters (649 [4%] cases) were included. VE against influenza-associated ED/UC encounters was 25% (95% confidence interval (CI), 20%-29%) and 25% (95% CI, 11%-37%) against influenza-associated hospitalizations. VE against ED/UC encounters was lower in adults ≥65 years of age (7%; 95% CI, -5% to 17%) or with immunocompromising conditions (4%; 95% CI, -45% to 36%). During an influenza A(H3N2)-predominant influenza season, modest VE was observed. These findings highlight the need for improved vaccines, particularly for A(H3N2) viruses that are historically associated with lower VE.

Active Duty Service Members Newly Presenting With Low Back Pain in Fiscal Year 2017: Health Care Utilization, Access to Care, and Private Sector Costs Over 2-year Follow-up.

Low back pain (LBP) has accounted for the most medical encounters every year for the past decade among Active Duty Service Members (ADSMs) of the U.S. Armed Forces. The objectives of this retrospective, descriptive study were to classify LBP by clinical category (Axial, Radicular, and Other) and duration (Acute, Subacute, and Chronic) and examine the LBP-related health care utilization, access to care, and private sector costs for ADSMs over a 2-year follow-up period. The Military Health System Data Repository was queried in fiscal year 2017 for all ADSMs (ages 18-62) with outpatient encounters documented with any of 67 ICD-10 diagnosis codes indicative of LBP. A 1-year clean period before the first (index) outpatient LBP encounter date was used to ensure no recent history of LBP care. Patients were eligible if continuously enrolled and on active duty for 1 year before and 2 years following the index visit. Patients were excluded for non-musculoskeletal causes for LBP, red flags, or acute trauma within 4 weeks of the index visit and/or systemic illness or pregnancy anytime during the clean or follow-up period. A total of 52,118 ADSMs met the inclusion criteria, and the cohort was classified by duration of LBP symptoms as Acute [17,916 (34.4%)], Subacute [4,119 (7.9%)], and Chronic [30,083 (57.7%)]. Over 2-year follow-up, 419,983 outpatient visits were recorded, with the majority occurring at MTFs [363,570 (86.6%)]. 13,237 (25.4%) of ADSMs in the total cohort were documented with no other LBP-related visits beyond their index encounter. In contrast, the Chronic cohort comprised the highest number of encounters [371,031 (89.2% of total encounters)], including 86% of imaging studies performed for LBP, and accounted for $9,986,606.17 (94.9%) of total private sector costs over the 2-year follow-up period. Interventional pain procedures ($2,983,767.50) and physical therapy ($2,298,779.07) represented the costliest categories in the private sector for the Chronic cohort, whereas Emergency Department ($283,307.43) and physical therapy ($137,035.54) encounters were the top contributors to private sector costs for the Acute and Subacute cohorts, respectively. Overall reliance on the private sector was highest for specialty care, including 10,721 (75.4%) interventional pain procedures and 306 (66.4%) spine surgeries. Uncovering current trends in health care utilization and access to care for ADSMs newly presenting with LBP is vital for timely and accurate diagnosis, as well as early intervention to prevent progression to chronic LBP and to minimize its negative impact on military readiness and quality of life. This retrospective, descriptive study highlights the burden of chronic LBP on health care utilization and costs within the Military Health System, including reliance on the private sector care, amounting to $10,524,332.04 over the study period.

Prostate Cancer Screening Disparities in Persons Experiencing Homelessness

<h3>Purpose/Objective(s)</h3> Persons experiencing homelessness (PEH) face barriers to cancer screening, leading to cancer diagnosis at more advanced stages. Data on prostate specific antigen (PSA) screening in this population is scarce. The aim of this study was to 1) assess PSA testing rates in PEH and identify factors associated with screening and 2) compare PSA screening rates in PEH with persons not experiencing homelessness (non-PEH). <h3>Materials/Methods</h3> This is an IRB approved study of PEH and non-PEH cared for at a large metropolitan hospital system from 2014 to 2021. We identified PEH from a prospective institutional registry which started screening for homelessness in January 2014. Homelessness was defined by either the presence of the Z-code for homelessness (Z59) within the medical record, the listed address was matched to homeless shelters or other transitional housing, or the patient identified as homeless. Institutional CPT and HCPCS billing codes for PSA testing were available beginning 01/01/2017 and cross-referenced to identify patients who underwent PSA testing at least once between 01/01/2017 and 12/31/2021. We extracted PSA testing information for a matched cohort of non-PEH based on sex, age, county of residence, and date of last encounter for comparison. We included men ages 50-69 that lived in our institution's county or an immediately adjacent county. The primary outcome was to assess the rate of PSA testing in the past 5 years in accordance with national screening guidelines (USPSTF, AUA, ACS) and to identify factors associated with PSA testing in PEH. <h3>Results</h3> A total of 9,249 PEH were identified, with 1,605 eligible for PSA screening (men between ages 50-69) within the study timeframe; 3,421 non-PEH were eligible for screening comparison. The median age of PEH was 58.0 years old and the majority of PEH were Black (50%) or White (43%). 67% of PEH were current tobacco users, 52% current alcohol users, and 34% current illicit drug users. Medicaid was the most common insurance (51%) followed by Medicare (19%) and private insurance (4%). PEH were less likely to have a PCP (58% vs 81%, p<0.001) and had a significantly lower PSA testing rate (13% vs 34%, p<0.001) compared to non-PEH. On univariate analysis, PEH were more likely to be Black (p<0.001), single (p<0.001), unemployed (p<0.001) and have Medicaid/no insurance (p<0.001). On multivariate analysis, each of these associations remained significant; most notably, lack of a PCP (OR=1.78; 95% CI 1.35-2.30, p<0.001) or PSA testing (OR=1.63; 95% CI, 1.25-2.14, p<0.001) were associated with increased odds of being homeless. Within the homeless population, multivariate analysis showed that having a PCP (OR=2.58; 95% CI, 1.64-4.05) significantly increased the odds of getting PSA testing. <h3>Conclusion</h3> PEH experience low rates of prostate cancer screening. Interventions to increase screening in this population, including increased PCP access, are warranted.

Frequency of SARS-CoV-2 Positivity Among Children Presenting With Gastroenteritis in Emergency Department.

To the Editors: SARS-CoV-2 infection typically presents with respiratory symptoms, such as rhinitis, cough and dyspnea.1 Although children affected by SARS-CoV-2 might also present uniquely with vomiting or diarrhea,2 the frequency of SARS-CoV-2 positivity among children presenting with an acute gastroenteritis is currently unknown.3,4 The primary aim of this study was to investigate the frequency of SARS-CoV-2 positivity among children with gastroenteritis. The secondary aims were to compare the frequency of SARS-CoV-2 positivity among children with gastroenteritis, with an acute respiratory disease or without any symptom of infection. At the emergency department (ED) of the Fondazione Ca’ Granda Policlinico, Milan, Italy, children presenting with gastroenteritis or a respiratory disease undergo a nasopharyngeal swab for the detection of SARS-CoV-2 by a molecular test. Children requiring an immediate hospitalization are also tested, regardless of their symptoms.5 For this study, we included all children <18 years of age visiting the ED from December 21, 2020, to March 20, 2022, with gastroenteritis (ie, >3 episodes of vomiting or diarrhea in 24 hours). For each child with gastroenteritis, one child with a respiratory disease (rhinitis, cough or dyspnea) and one child requiring hospitalization for conditions without any symptom of infection (eg, trauma) during the same period were included. These children were matched for age (±6 months) and encounter date (±10 days) with those presenting with gastroenteritis. Subjects with both gastrointestinal and respiratory symptoms or without a SARS-CoV-2 swab test were excluded. Children reporting a close contact with a subject with SARS-CoV-2 in the previous 7 days were also excluded. Information on age, sex, date of encounter and the presence of fever (≥37.5 °C) was retrospectively extracted. Data are given as median and interquartile range or frequency, percentage and 95% confidence interval (CI). The χ2-test was used to compare the frequency of SARS-CoV-2 positivity among the 3 study groups. In the study period, 423 children presented to the ED with acute gastroenteritis. The molecular test for SARS-CoV-2 was not available in 13 children. Therefore, 410 children [3.7 (1.4–8.2) years] with gastroenteritis, 410 with a respiratory disease and 410 hospitalized without any infectious symptom were included (Table 1). Fever was more frequent (P < 0.001) in children with respiratory disease than in those with gastroenteritis. The prevalence of SARS-CoV-2 positivity was similar in children with gastroenteritis and with a respiratory disease [8.0% (5.6%–11%) vs. 6.6% (4.4%–9.4%), respectively; P = 0.5], and lower in those without any infectious symptom [3.2% (1.7%–5.4%); P = 0.004]. Among children with fever, those with gastroenteritis and those with a respiratory disease had a similar frequency of SARS-CoV-2 positivity [8.8% (5.3%–14%) vs. 6.0% (3.5%–9.6); P = 0.3]. TABLE 1. - Characteristics of Children With Acute Gastroenteritis, Respiratory Disease or Without Any Symptom of Infection Admitted to the ED Between December 21, 2020, and March 20, 2022 Gastroenteritis Respiratory Disease No Symptom N 410 410 410 Age, y 3.9 [1.5–8.3] 3.4 [1.4–6.8] 3.9 [1.2–8.7] Male 239 (58) 231 (56) 243 (59) Fever 205 (50) 265 (65)* 0 SARS-CoV-2 positivity 33 (8.0)§ 27 (6.6)‡ 13 (3.2)† Children of the 3 groups are matched for age and encounter date. Data are presented as median and interquartile range or frequency and percentage (%).*P < 0.001 gastroenteritis vs. respiratory disease.‡P = 0.5 gastroenteritis vs. respiratory disease.§P = 0.004 gastroenteritis vs. no symptom.†P = 0.034 respiratory disease vs. no symptom. These data suggest that the frequency of SARS-CoV-2 is similar in cases with acute gastroenteritis and with a respiratory disease. Furthermore, both children with respiratory disease and gastroenteritis are more frequently SARS-CoV-2 positive than children without any symptom of infection. Although data were retrospectively collected in a single center, this study has potential implications for clinicians and health policymakers and helps assessing the pretest probability of SARS-CoV-2 positivity among children in ED.